{"content":"<li class=\"n-box-item date-title\" data-end=\"1499831999\" data-start=\"1499745600\" data-txt=\"Monday, December 23, 2019\">Tuesday, July 11, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3278072\" data-ts=\"1499812019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDSY\" target=\"_blank\">IDSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278072-i-d-systems-to-acquire-keytroller-sharesplus-3_4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">I.D. Systems to acquire Keytroller; shares +3.4%</a></h4><ul>   <li>I.D. Systems (<a href=\"http://seekingalpha.com/symbol/IDSY\" target=\"_blank\">IDSY</a> <font color='red'>-11.3%</font>) has a deal to <a href=\"https://seekingalpha.com/pr/16884076-d-systems-acquire-keytroller-strengthening-position-industrial-truck-management-market\" target=\"_blank\">acquire the assets of Keytroller</a>, which makes electronic products to manage industrial equipment.</li>    <li>Shares are <font color='green'>up 3.4%</font> after hours.</li>    <li>I.D. Systems will pay $9M ($7M in cash and $2M in common stock) along with up to a $3M stock earn-out over two years.</li>    <li>Keytroller posted revenue of $6.6M and EBITDA of $1.2M in 2016. The deal's expected to close by the end of July.</li>    <li>Also, I.D. Systems is setting a <a href=\"https://seekingalpha.com/pr/16884077-d-systems-announces-proposed-underwritten-public-offering\" target=\"_blank\">public offering to fund the acquisition</a>. B. Riley will be sole book-runner.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278072\" data-linked=\"I.D. Systems to acquire Keytroller; shares +3.4%\" data-tweet=\"$IDSY $PWFL - I.D. Systems to acquire Keytroller; shares +3.4% https://seekingalpha.com/news/3278072-i-d-systems-to-acquire-keytroller-sharesplus-3_4?source=tweet\" data-url=\"https://seekingalpha.com/news/3278072-i-d-systems-to-acquire-keytroller-sharesplus-3_4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278070\" data-ts=\"1499811403\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDR\" target=\"_blank\">ALDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278070-alder-biominus-9-on-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alder Bio -9% on capital raise</a></h4><ul><li>The company is putting up for sale 12.5M shares of common stock. The underwriter greenshoe is for up to another 1.875M shares.</li><li>The current float is about 50M shares.</li><li><a href='https://seekingalpha.com/symbol/ALDR' title='Alder Biopharmaceuticals Inc.'>ALDR</a><font color='red'> -9%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3278070\" data-linked=\"Alder Bio -9% on capital raise\" data-tweet=\"$ALDR - Alder Bio -9% on capital raise https://seekingalpha.com/news/3278070-alder-biominus-9-on-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3278070-alder-biominus-9-on-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278064\" data-ts=\"1499809030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278064-ocular-therapeutixminus-30-fda-denies-nda-for-dextenza\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocular Therapeutix -30% as FDA denies NDA for Dextenza</a></h4><ul>   <li>Ocular Therapeutix (NASDAQ:<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a>) -- <font color='green'>up 17.1%</font> during market hours, after last night's <a href=\"https://seekingalpha.com/news/3277795-ocular-submits-amendment-dextenza-nda-equipment-change-closes-form-483-issues-fda-action-date\" target=\"_blank\">amendment filing</a> for an equipment change on Dextenza -- has come out of a halt <font color='red'>down 30%</font> after hours, following an FDA letter denying its NDA.</li>    <li>The complete response letter says the FDA can't approve Dextenza's NDA in its current form. The agency received the equipment amendment but couldn't review it before taking action.</li>    <li>Meanwhile, Ocular chief Amar Sawhney expects the resolution of manufacturing issues to lead to Dextenza's approval in time.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278064\" data-linked=\"Ocular Therapeutix -30% as FDA denies NDA for Dextenza\" data-tweet=\"$OCUL - Ocular Therapeutix -30% as FDA denies NDA for Dextenza https://seekingalpha.com/news/3278064-ocular-therapeutixminus-30-fda-denies-nda-for-dextenza?source=tweet\" data-url=\"https://seekingalpha.com/news/3278064-ocular-therapeutixminus-30-fda-denies-nda-for-dextenza\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>60&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278063\" data-ts=\"1499808970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278063-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/COHU' title='Cohu, Inc.'>COHU</a> <font color='green'>+8.8%</font>. <a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a> <font color='green'>+4.4%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='green'>+3.0%</font>. <a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a> <font color='green'>+2.0%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/ALDR' title='Alder Biopharmaceuticals Inc.'>ALDR</a> <font color='red'>-8.2%</font>. <a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='red'>-2.1%</font>. <a href='https://seekingalpha.com/symbol/AUY' title='Yamana Gold Inc.'>AUY</a> <font color='red'>-1.3%</font>. <a href='https://seekingalpha.com/symbol/CYOU' title='Changyou.com Limited'>CYOU</a> <font color='red'>-1.2%</font>. <a href='https://seekingalpha.com/symbol/ENB' title='Enbridge Inc.'>ENB</a> <font color='red'>-1.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278063\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$COHU $TAHO $SND - After Hours Gainers / Losers https://seekingalpha.com/news/3278063-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3278063-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278053\" data-ts=\"1499806646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZBH\" target=\"_blank\">ZBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278053-zimmer-sees-q2-top-line-of-1_954b-eps-of-2_08-shares-down-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zimmer sees Q2 top line of $1.954B, EPS of ~$2.08; shares down 2% after hours</a></h4><ul><li>Zimmer Biomet Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZBH' title='Zimmer Biomet Holdings, Inc.'>ZBH</a>) <a href=\"https://seekingalpha.com/pr/16884002-zimmer-biomet-reports-certain-preliminary-second-quarter-2017-results\" target=\"_blank\">expects </a>Q2 revenues of ~$1.954B, up 1.1% yoy and near the lower end of its previously announced range of $1.940B - 1.960B.</li><li>Non-GAAP EPS should also come in near the bottom of its previously announced range of $2.08 - 2.13.</li><li>Further details and updated guidance will be released on Thursday, July 27 during its earnings call.</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;after hours on increased volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278049-zimmer-biomet-chief-steps-shares-ease-2-percent-hours\" target=\"_blank\">Zimmer Biomet chief steps down; shares ease 2% after hours</a> (July 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278053\" data-linked=\"Zimmer sees Q2 top line of $1.954B, EPS of ~$2.08; shares down 2% after hours\" data-tweet=\"$ZBH - Zimmer sees Q2 top line of $1.954B, EPS of ~$2.08; shares down 2% after hours https://seekingalpha.com/news/3278053-zimmer-sees-q2-top-line-of-1_954b-eps-of-2_08-shares-down-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3278053-zimmer-sees-q2-top-line-of-1_954b-eps-of-2_08-shares-down-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278049\" data-ts=\"1499806064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZBH\" target=\"_blank\">ZBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278049-zimmer-biomet-chief-steps-down-shares-ease-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zimmer Biomet chief steps down; shares ease 2% after hours</a></h4><ul><li>Zimmer Biomet Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZBH' title='Zimmer Biomet Holdings, Inc.'>ZBH</a>) President &amp; CEO David Dvorak has <a href=\"https://seekingalpha.com/pr/16883982-zimmer-biomet-announces-leadership-transition\" target=\"_blank\">resigned</a> effective today. He will continue to serve as an advisor for a period of time.</li><li>SVP and CFO Daniel Florin will take over on an interim basis until a permanent successor is named.</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278049\" data-linked=\"Zimmer Biomet chief steps down; shares ease 2% after hours\" data-tweet=\"$ZBH - Zimmer Biomet chief steps down; shares ease 2% after hours https://seekingalpha.com/news/3278049-zimmer-biomet-chief-steps-down-shares-ease-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3278049-zimmer-biomet-chief-steps-down-shares-ease-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278048\" data-ts=\"1499805967\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATUS\" target=\"_blank\">ATUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278048-guggenheim-starts-altice-usa-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guggenheim starts Altice USA at Buy</a></h4><ul>   <li>Guggenheim has launched coverage of Altice USA (<a href=\"http://seekingalpha.com/symbol/ATUS\" target=\"_blank\">ATUS</a> <font color='red'>-1.6%</font>) at Buy.</li>    <li>It joins Pivotal as the other firm with a Buy rating on the stock, which priced its initial public offering <a href=\"https://seekingalpha.com/news/3274923-altice-usa-prices-initial-public-offering-30\" target=\"_blank\">three weeks ago at $30</a>. (Shares fell to $31.75 today).</li>    <li>Like Pivotal, Guggenheim has set a price target of $38, implying 19.7% upside from today's lower price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278048\" data-linked=\"Guggenheim starts Altice USA at Buy\" data-tweet=\"$ATUS - Guggenheim starts Altice USA at Buy https://seekingalpha.com/news/3278048-guggenheim-starts-altice-usa-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3278048-guggenheim-starts-altice-usa-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278045\" data-ts=\"1499805876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COHU\" target=\"_blank\">COHU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278045-cohu-updates-guidance-for-q2-sharesplus-5-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cohu updates guidance for Q2; Shares +5% AH</a></h4><ul>     <li>Cohu (NASDAQ:<a href='https://seekingalpha.com/symbol/COHU' title='Cohu, Inc.'>COHU</a>) <a href=\"https://seekingalpha.com/pr/16883993-cohu-announces-strong-preliminary-second-quarter-2017-results\" target=\"_blank\">now expects</a> Q2 revenue of ~$93M (+22% Y/Y) vs. a consensus of $86.17M and prior guidance of ~$86M.</li>     <li>GM in-line with previous non-GAAP guidance of ~40%.</li>     <li>Operating expenses ~$1M higher than previous non-GAAP guidance of ~$22M, due to foreign currency losses.</li>     <li>The company projects 2H17 sales to be approximately the same as 1H17</li><li>Shares&nbsp;<font color='green'>+5%&nbsp;</font>AH.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278045\" data-linked=\"Cohu updates guidance for Q2; Shares +5% AH\" data-tweet=\"$COHU - Cohu updates guidance for Q2; Shares +5% AH https://seekingalpha.com/news/3278045-cohu-updates-guidance-for-q2-sharesplus-5-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/3278045-cohu-updates-guidance-for-q2-sharesplus-5-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278044\" data-ts=\"1499805729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNA\" target=\"_blank\">ARNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278044-arena-readies-150m-stock-offering-shares-slip-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arena readies $150M stock offering; shares slip 1% after hours</a></h4><ul><li>Arena Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a>) is down&nbsp;<font color='red'>1%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16883944-arena-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">planned public offering</a> of $150M of common stock. Underwriters over-allotment will be an additional $22.5M of shares. Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278044\" data-linked=\"Arena readies $150M stock offering; shares slip 1% after hours\" data-tweet=\"$ARNA - Arena readies $150M stock offering; shares slip 1% after hours https://seekingalpha.com/news/3278044-arena-readies-150m-stock-offering-shares-slip-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3278044-arena-readies-150m-stock-offering-shares-slip-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278041\" data-ts=\"1499805330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCSG\" target=\"_blank\">HCSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278041-healthcare-services-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare Services beats by $0.01, beats on revenue</a></h4><ul><li>Healthcare Services (NASDAQ:<a href='https://seekingalpha.com/symbol/HCSG' title='Healthcare Services Group, Inc.'>HCSG</a>): Q2 EPS of $0.30 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $470.87M (+21.8% Y/Y) <font color='green'>beats by $45.63M</font>.</li><li>Shares <font color='green'>+3.9%</font>.</li><li><a href='https://seekingalpha.com/pr/16883970-healthcare-services-group-inc-reports-results-three-six-months-ended-june-30-2017-announces'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3278041\" data-linked=\"Healthcare Services beats by $0.01, beats on revenue\" data-tweet=\"$HCSG - Healthcare Services beats by $0.01, beats on revenue https://seekingalpha.com/news/3278041-healthcare-services-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3278041-healthcare-services-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278036\" data-ts=\"1499805007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KIN\" target=\"_blank\">KIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278036-kindred-bio-readies-equity-offering-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kindred Bio readies equity offering; shares down 3% after hours</a></h4><ul><li>Kindred Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/KIN' title='Kindred Biosciences, Inc.'>KIN</a>) <a href=\"https://seekingalpha.com/pr/16883948-kindredbio-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Net proceeds will fund the expansion of its commercial infrastructure, manufacturing capacity, clinical development, working capital and general corporate purposes.</li><li>Shares are off&nbsp;<font color='red'>3%</font>&nbsp;after hours on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278036\" data-linked=\"Kindred Bio readies equity offering; shares down 3% after hours\" data-tweet=\"$KIN - Kindred Bio readies equity offering; shares down 3% after hours https://seekingalpha.com/news/3278036-kindred-bio-readies-equity-offering-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3278036-kindred-bio-readies-equity-offering-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278022\" data-ts=\"1499803734\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278022-twitter-names-segal-chief-financial-officer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter names Segal chief financial officer</a></h4><ul>    <li>Twitter (<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a> <font color='green'>+3.1%</font>) has named Ned Segal its <a href=\"https://seekingalpha.com/pr/16883909-twitter-announces-appointment-ned-segal-chief-financial-officer\" target=\"_blank\">chief financial officer</a> to replace Anthony Noto.</li>    <li>The move's effective in late August, and Noto will resume his role as chief operating officer.</li>    <li>Segal was most recently senior VP of finance for Intuit's Small Business Group (which manages QuickBooks, Payments, and Payrol).</li>    <li>He'll report to Jack Dorsey. Twitter reports earnings July 27.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278022\" data-linked=\"Twitter names Segal chief financial officer\" data-tweet=\"$TWTR - Twitter names Segal chief financial officer https://seekingalpha.com/news/3278022-twitter-names-segal-chief-financial-officer?source=tweet\" data-url=\"https://seekingalpha.com/news/3278022-twitter-names-segal-chief-financial-officer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278021\" data-ts=\"1499803711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBIV\" target=\"_blank\">VBIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278021-vbi-vaccines-announces-phase-3-clinical-program-for-hepatitis-b-vaccine-sci-b-vac\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VBI Vaccines announces Phase 3 clinical program for Hepatitis B vaccine, Sci-B-Vac</a></h4><ul>     <li>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines'>VBIV</a>) <a href=\"https://seekingalpha.com/pr/16883942-vbi-vaccines-announces-phase-3-clinical-program-sci-b-vac-tm-hepatitis-b-vaccine\" target=\"_blank\">announces plans</a>&nbsp;for a global Phase 3 clinical program for Sci-B-Vac,its third-generation hepatitis B vaccine,following positive discussions with the USFDA, EMA and Health Canada.</li>     <li>The said program will consist of two concurrent phase 3 studies, safety and immunogenicity (PROTECT) and a lot-to-lot consistency study (CONSTANT).</li><li>The studies are expected to be 15-months in duration and enrolling ~4,800 subjects across ~40 sites in the U.S., Europe, and Canada.</li>     <li>The company will host a conference call and <a href=\"https://viavid.webcasts.com/starthere.jsp?ei=1154772&amp;tp_key=73a5c58496\" target=\"_blank\">webcast</a> on Wednesday, July12 at 8:30 am EDT, to provide a clinical and regulatory update on Sci-B-Vac.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274218-vbi-vaccines-advancing-sci-b-vac-u-s-ind-tap-h2-shares-ahead-6-percent-premarket\" target=\"_blank\">VBI Vaccines advancing Sci-B-VAc in U.S., IND on tap in H2; shares ahead 6% premarket</a> (June 19)</li><li>Shares&nbsp;<font color='green'>+3.5%</font>&nbsp;AH.</li><li>See important&nbsp;<a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278021\" data-linked=\"VBI Vaccines announces Phase 3 clinical program for Hepatitis B vaccine, Sci-B-Vac\" data-tweet=\"$VBIV - VBI Vaccines announces Phase 3 clinical program for Hepatitis B vaccine, Sci-B-Vac https://seekingalpha.com/news/3278021-vbi-vaccines-announces-phase-3-clinical-program-for-hepatitis-b-vaccine-sci-b-vac?source=tweet\" data-url=\"https://seekingalpha.com/news/3278021-vbi-vaccines-announces-phase-3-clinical-program-for-hepatitis-b-vaccine-sci-b-vac\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278010\" data-ts=\"1499802543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPCI\" target=\"_blank\">IPCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278010-intellipharmaceutics-follows-through-on-ad-com-stoked-up-move-shares-ahead-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intellipharmaceutics follows through on Ad Com-stoked up move, shares ahead 18%</a></h4><ul><li>Thinly traded nano cap Intellipharmaceutics (<a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='green'>+18.4%</font>) adds to its July 3 breakout on a healthy 6x surge in volume. Shares rallied after the company announced an FDA Ad Com meeting to be held on July 26 to review its Rexista NDA.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3276772-intellipharmaceutics-shares-9_5-percent-fda-meeting-news\" target=\"_blank\">Intellipharmaceutics shares up 9.5% on FDA meeting news</a> (July 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278010\" data-linked=\"Intellipharmaceutics follows through on Ad Com-stoked up move, shares ahead 18%\" data-tweet=\"$IPCI - Intellipharmaceutics follows through on Ad Com-stoked up move, shares ahead 18% https://seekingalpha.com/news/3278010-intellipharmaceutics-follows-through-on-ad-com-stoked-up-move-shares-ahead-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3278010-intellipharmaceutics-follows-through-on-ad-com-stoked-up-move-shares-ahead-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278008\" data-ts=\"1499801772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORE\" target=\"_blank\">CORE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278008-core-mark-breaks-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Core-Mark breaks higher</a></h4><ul>     <li>Core-Mark Holding (<a href='https://seekingalpha.com/symbol/CORE' title='Core-Mark Holding Company, Inc.'>CORE</a> <font color='green'>+7%</font>) rallies after the company completes the acquisition of Farner-Bocken Company.</li><li>Investors may also be reacting to a new deal by Core-Mark customer&nbsp;Couche-Tard to expand its distribution in the Midwest and the shedding of a Sell rating from Off Wall Street.</li><li>Core-Mark trades at its highest level since the Amazon acquisition of Whole Foods disrupted the grocery sector.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278008\" data-linked=\"Core-Mark breaks higher\" data-tweet=\"$CORE - Core-Mark breaks higher https://seekingalpha.com/news/3278008-core-mark-breaks-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3278008-core-mark-breaks-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278006\" data-ts=\"1499801387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278006-mallinckrodt-finalizes-settlements-related-to-government-investigations-distribution-of\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mallinckrodt finalizes settlements related to government investigations into distribution of controlled substances, agrees to pay $35M; shares ahead 2%</a></h4><ul><li>Without admitting guilt in the U.S. government's investigation into potential illegal activity related to its manufacture and distribution of controlled substances, Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='green'>+2.1%</font>)<a href=\"https://seekingalpha.com/pr/16883834-mallinckrodt-finalizes-previously-announced-agreement-dea-usaos\" target=\"_blank\"> agrees to pay</a> $35M to settle all potential claims by the U.S. Drug Enforcement Administration &#40;DEA&#41; and U.S. Attorneys' Offices in Michigan and New York.</li><li>The company says the settlement will have no material adverse effect on its financial condition, operations or cash flows since it had already created a reserve for the full amount.</li><li>Mallinckrodt General Counsel Michael-Bryant Hicks says, \"While Mallinckrodt disagreed with the&nbsp;U.S.&nbsp;government's allegations, we chose to resolve the legacy matter in order to eliminate the uncertainty, distraction and expense of litigation and to allow the company to focus on meeting the important needs of its patients and customers.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3278006\" data-linked=\"Mallinckrodt finalizes settlements related to government investigations into distribution of controlled substances, agrees to pay $35M; shares ahead 2%\" data-tweet=\"$MNK - Mallinckrodt finalizes settlements related to government investigations into distribution of controlled substances, agrees to pay $35M; shares ahead 2% https://seekingalpha.com/news/3278006-mallinckrodt-finalizes-settlements-related-to-government-investigations-distribution-of?source=tweet\" data-url=\"https://seekingalpha.com/news/3278006-mallinckrodt-finalizes-settlements-related-to-government-investigations-distribution-of\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278004\" data-ts=\"1499800979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ULTA\" target=\"_blank\">ULTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278004-cosmetics-stocks-hit-on-concerns-of-discounting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cosmetics stocks hit on concerns of discounting</a></h4><ul><li>Ulta Beauty (<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a> <font color='red'>-4.4%</font>), Estee Lauder (<a href='https://seekingalpha.com/symbol/EL' title='Estee Lauder Companies, Inc. &#40;The&#41;'>EL</a> <font color='red'>-0.6%</font>)&nbsp;and e.l.f. Beauty (<a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty'>ELF</a> <font color='red'>-2.2%</font>) trade lower after The Wall Street Journal <a href=\"https://www.wsj.com/articles/the-cosmetics-counter-was-long-immune-to-discounting-not-anymore-1499679001\" target=\"_blank\">highlights</a> the heavy discounting of cosmetics products by department stores in a bid to gain back market share.</li><li>Oppenheimer recommends buying shares of Ulta on the weakness due to the company's strong fundamentals.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278004\" data-linked=\"Cosmetics stocks hit on concerns of discounting\" data-tweet=\"$ULTA $ULTA $EL - Cosmetics stocks hit on concerns of discounting https://seekingalpha.com/news/3278004-cosmetics-stocks-hit-on-concerns-of-discounting?source=tweet\" data-url=\"https://seekingalpha.com/news/3278004-cosmetics-stocks-hit-on-concerns-of-discounting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278000\" data-ts=\"1499799601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278000-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/PNTR' title='Pointer Telocation Ltd.'>PNTR</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/DYSL' title='Dynasil Corporation of America'>DYSL</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a> <font color='green'>+9%</font>. FH <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/RSYS' title='RadiSys Corporation'>RSYS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278000\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$QBAK $PNTR $DYSL - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3278000-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3278000-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277994\" data-ts=\"1499798484\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVN\" target=\"_blank\">DVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277994-devon-energy-reports-record-production-rate-for-stack-well\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Devon Energy reports record production rate for STACK well</a></h4><ul>     <li>Devon Energy (<a href='https://seekingalpha.com/symbol/DVN' title='Devon Energy Corporation'>DVN</a> <font color='green'>+3.3%</font>) reports a production rate of 6K boe/day from a well in Oklahoma, which it says sets a <a href=\"https://seekingalpha.com/pr/16882550-devon-energy-announces-record-stack-well-reaching-6000-boe-per-day-provides-development\" target=\"_blank\">new initial production record for the STACK play</a> of Oklahoma \"by a wide margin.\"</li>     <li>DVN expects the Privott 17-H well to recover more than 2M boe; initial production was 50% oil.</li>     <li>DVN says it also brought online four other high-rate wells in the area during Q2 which attained an average 30-day initial production rate of 2K boe/day.</li><li>DVN says its STACK position encompasses more than 600K       net acres by formation and is concentrated in the economic core of the       play.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277994\" data-linked=\"Devon Energy reports record production rate for STACK well\" data-tweet=\"$DVN - Devon Energy reports record production rate for STACK well https://seekingalpha.com/news/3277994-devon-energy-reports-record-production-rate-for-stack-well?source=tweet\" data-url=\"https://seekingalpha.com/news/3277994-devon-energy-reports-record-production-rate-for-stack-well\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277990\" data-ts=\"1499797582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277990-verastem-continues-up-move-shares-ahead-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verastem continues up move, shares ahead 20%</a></h4><ul><li>Micro cap Verastem (<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+20%</font>) heads north on more than triple normal volume. Shares have rallied over&nbsp;<font color='green'>85%</font>&nbsp;this month and over&nbsp;<font color='green'>265%</font>&nbsp;since March.</li><li>Investors appear to be taking long positions on rosy expectations for blood cancer candidate duvelisib.</li><li>A few weeks ago, the company <a href=\"https://seekingalpha.com/pr/16870934-verastem-reports-phase-2-long-term-follow-data-duvelisib-patients-double-refractory\" target=\"_blank\">reported </a>long-term follow-up data from a Phase 2 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01882803?term=duvelisib&amp;titles=dynamo&amp;rank=1\" target=\"_blank\">DYNAMO</a>, that assessed duvelisib in patients with treatment-resistant indolent non-Hodgkin lymphoma. At 18 months, the overall response rate &#40;ORR&#41; in a subgroup of double-refractory follicular lymphoma was 43% (n=36/83), almost all (n=35/36) partial responders. Median duration of response was 7.9 months, median progression-free survival was 8.3 months and median overall survival was 27.8 months.</li><li>In a subgroup of patients with double-refractory small lymphocytic lymphoma &#40;SLL&#41;, the ORR was 68% (n=19/28). All experienced a reduction in the size of their target lymph nodes.</li><li>Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.</li><li>Top-line data from a Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02004522?term=duvelisib&amp;phase=2&amp;rank=3\" target=\"_blank\">DUO</a>, comparing duvelisib to Novartis' <a href=\"https://www.us.arzerra.com/?site=43700015041484002&amp;source=01030\" target=\"_blank\">ARZERRA </a>(ofatumumab) in treatment-resistant CLL and SLL should be available in Q4. A <a href=\"https://clinicaltrials.gov/ct2/show/NCT02049515?term=duvelisib&amp;phase=2&amp;rank=4\" target=\"_blank\">Phase 3 extension study</a> is currently recruiting patients.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3272358-veratem-present-long-term-follow-data-duvelisib-next-week-shares-ahead-10-percent-premarket\" target=\"_blank\">Verastem to present long-term follow-up data on duvelisib next week; shares ahead 10% premarket</a> (June 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277990\" data-linked=\"Verastem continues up move, shares ahead 20%\" data-tweet=\"$VSTM - Verastem continues up move, shares ahead 20% https://seekingalpha.com/news/3277990-verastem-continues-up-move-shares-ahead-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3277990-verastem-continues-up-move-shares-ahead-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277991\" data-ts=\"1499797482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WLB\" target=\"_blank\">WLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277991-westmoreland-coal-to-sell-1m-coal-tons-kemmerer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Westmoreland Coal to sell 1M more coal tons at Kemmerer</a></h4><ul><li>Westmoreland Coal (<a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+3.8%</font>) shoots higher after unveiling an amended agreement with PacifiCorp to <a href=\"https://seekingalpha.com/pr/16883695-westmoreland-coal-company-announces-additional-coal-sales-kemmerer-2018\" target=\"_blank\">sell ~1M additional tons of coal</a> during 2018 than previously expected.</li><li>WLB says the additional sales are the result of  PacifiCorp's plan to extend its Naughton Unit 3 operations through the end of  2018.</li><li>WLB serves PacifiCorp through its Kemmerer mine, part of its Westmoreland Resource Partners (<a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-19.9%</font>) affiliate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277991\" data-linked=\"Westmoreland Coal to sell 1M more coal tons at Kemmerer\" data-tweet=\"$WLB $WLB $WMLP-OLD - Westmoreland Coal to sell 1M more coal tons at Kemmerer https://seekingalpha.com/news/3277991-westmoreland-coal-to-sell-1m-coal-tons-kemmerer?source=tweet\" data-url=\"https://seekingalpha.com/news/3277991-westmoreland-coal-to-sell-1m-coal-tons-kemmerer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277986\" data-ts=\"1499796538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMFW\" target=\"_blank\">AMFW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277986-amec-foster-wheeler-is-subject-of-sfo-investigation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amec Foster Wheeler is subject of SFO investigation</a></h4><ul>     <li>Amec Foster Wheeler (<a href='https://seekingalpha.com/symbol/AMFW' title='Amec Foster Wheeler plc'>AMFW</a> <font color='red'>-3.2%</font>) tumbles after  confirming that the  U.K.'s Serious Fraud Office has <a href=\"http://www.lse.co.uk/AllNews.asp?code=ehwhxodo&amp;headline=TOP_NEWS_Amec_Foster_Wheeler_Is_Subject_Of_Serious_Fraud_Office_Probe\" target=\"_blank\">opened an investigation</a> into the company's past use of third parties and possible bribery and corruption.</li><li>The company disclosed in May that the SFO could launch such a probe.</li><li>AMFW does not expect the investigation to affect the completion of its merger with Wood Group (<a href='https://seekingalpha.com/symbol/WDGJF' title='Wood Group &#40;John&#41; Plc.'>OTCPK:WDGJF</a>), which should occur in Q4  2017.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3277986\" data-linked=\"Amec Foster Wheeler is subject of SFO investigation\" data-tweet=\"$AMFW $AMFW $WDGJF - Amec Foster Wheeler is subject of SFO investigation https://seekingalpha.com/news/3277986-amec-foster-wheeler-is-subject-of-sfo-investigation?source=tweet\" data-url=\"https://seekingalpha.com/news/3277986-amec-foster-wheeler-is-subject-of-sfo-investigation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277983\" data-ts=\"1499796090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277983-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a> <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc Ordinary Sh'>HBM</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/TMST' title='TimkenSteel Corp.'>TMST</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CNX' title='CNX Resources Corporation'>CNX</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277983\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$HKRS $TRNX $HBM - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3277983-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3277983-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277969\" data-ts=\"1499793636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277969-financials-top-5-gainers-losers-of-1-20-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:20 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+9%</font>.AHP <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GTY' title='Getty Realty Corp.'>GTY</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277969\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:20 PM\" data-tweet=\"$MLP $YRD $BHR - Financials - Top 5 Gainers / Losers as of 1:20 PM https://seekingalpha.com/news/3277969-financials-top-5-gainers-losers-of-1-20-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3277969-financials-top-5-gainers-losers-of-1-20-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277963\" data-ts=\"1499791640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277963-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='green'>+46%</font>. <a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a> <font color='green'>+46%</font>. <a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ACY' title='Aerocentury Corp'>ACY</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SIEN' title='Sientra'>SIEN</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/NVCR' title='NovoCure'>NVCR</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/PNTR' title='Pointer Telocation Ltd.'>PNTR</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/MSON' title='MISONIX, Inc.'>MSON</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SHLO' title='Shiloh Industries, Inc.'>SHLO</a> <font color='red'>-13%</font>. PSDV <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='red'>-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277963\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ARNA $HKRS $FOLD - Midday Gainers / Losers https://seekingalpha.com/news/3277963-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3277963-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277955\" data-ts=\"1499788926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277955-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='red'>-19%</font>. KORS <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/HELE' title='Helen of Troy Limited'>HELE</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/RIBT' title='RiceBran Technologies'>RIBT</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277955\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NBEV $NAKD $VOXX - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3277955-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3277955-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277949\" data-ts=\"1499786405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277949-whole-foods-market-perks-up-amid-costco-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whole Foods Market perks up amid Costco chatter</a></h4><ul> <li>Shares of Whole Foods (WFM) are showing some vitality off rumors of interest by Costco (<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a> <font color='green'>+1%</font>) in making a bid.</li> <li>The chatter indicates that Costco is prepping for a $15B offer for the grocery store chain.</li> <li>Whote Foods trades at $42.08 vs. the $42.00 deal price from Amazon.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277949\" data-linked=\"Whole Foods Market perks up amid Costco chatter\" data-tweet=\"$AMZN $AMZN $COST - Whole Foods Market perks up amid Costco chatter https://seekingalpha.com/news/3277949-whole-foods-market-perks-up-amid-costco-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3277949-whole-foods-market-perks-up-amid-costco-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277946\" data-ts=\"1499785697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277946-pareteum-stock-nearly-doubles-on-upbeat-q2-numbers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum stock nearly doubles on upbeat Q2 numbers</a></h4><ul>   <li>Pareteum (<a href=\"http://seekingalpha.com/symbol/TEUM\" target=\"_blank\">TEUM</a> <font color='green'>+93%</font>) shares have nearly doubled in trading on dozens of times normal volume after a <a href=\"https://seekingalpha.com/pr/16882728-pareteum-sets-q2-2017-results-announcement-date-anticipates-revenues-exceed-expectations\" target=\"_blank\">sunny forecast</a> for its upcoming Q2 earnings.</li>    <li>The former Elephant Talk set its announcement date and conference call as on or before Aug. 14, and says it's expecting revenues to top $3M for the quarter.</li>    <li>Its contracted backlog stands at $60M and growing, \"an important inflection point\" for the business, says Executive Chairman Hal Turner. \"Pareteum's approximate $60M 36-month revenue backlog at the end of the second quarter is almost triple the number at the beginning of 2016.\"</li>    <li>\"More importantly, because of five new sales agreements, including additions for our large existing customers, and new customers, we have increased by almost 50% the backlog since I first reported it at $44M during our Q1 Town Hall call.\"</li>    <li>Shares had lost 74% of value over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277946\" data-linked=\"Pareteum stock nearly doubles on upbeat Q2 numbers\" data-tweet=\"$TEUM - Pareteum stock nearly doubles on upbeat Q2 numbers https://seekingalpha.com/news/3277946-pareteum-stock-nearly-doubles-on-upbeat-q2-numbers?source=tweet\" data-url=\"https://seekingalpha.com/news/3277946-pareteum-stock-nearly-doubles-on-upbeat-q2-numbers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277945\" data-ts=\"1499785611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOL\" target=\"_blank\">TOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277945-homebuilders-slide-barclays-downgrades-several-names\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Homebuilders slide as Barclays downgrades several names</a></h4><ul>     <li>Homebuilder stocks are broadly lower after Barclays issues a round of <a href=\"http://www.marketwatch.com/story/homebuilder-stocks-fall-after-several-downgrades-at-barclays-2017-07-11\" target=\"_blank\">downgrades</a>, saying expectations have run up too high as key indicators including moderating buyer traffic trends show limited upside even as demand remains robust.</li>     <li>Barclays downgrades Toll Brothers (<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers Inc.'>TOL</a> <font color='red'>-2.2%</font>) to Underweight from Equal Weight, and cuts Lennar (<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a> <font color='red'>-2%</font>), PulteGroup (<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a> <font color='red'>-1.6%</font>) and TRI Pointe Homes (<a href='https://seekingalpha.com/symbol/TPH' title='TRI Pointe Group, Inc.'>TPH</a> <font color='red'>-2%</font>) to Equal Weight from Overweight; KB&nbsp;Home (<a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a> <font color='red'>-0.7%</font>), Meritage Homes (<a href='https://seekingalpha.com/symbol/MTH' title='Meritage Homes Corporation'>MTH</a> <font color='red'>-1.4%</font>) and Realogy Holdings (<a href='https://seekingalpha.com/symbol/RLGY' title='Realogy Holdings'>RLGY</a> <font color='red'>-0.7%</font>) are reiterated at Underweight, but CalAtlantic (<a href='https://seekingalpha.com/symbol/CAA' title='CalAtlantic Group, Inc.'>CAA</a> <font color='green'>+0.4%</font>) is upgraded to Equal Weight from Underweight because of the stock's recent underperformance vs. the group.</li>     <li>\"Our June A.G.E.N.T. Survey indicated moderating buyer traffic trends, warning of risk that near-term catalysts for builders will disappoint relative to rising expectations,\" according to analyst Michael Dahl, who also sees margin headwinds in land, labor and material costs.</li>     <li>Among other names in the sector: <a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a> <font color='red'>-0.8%</font>, <a href='https://seekingalpha.com/symbol/DHI' title='D. R. Horton Inc.'>DHI</a> <font color='red'>-0.9%</font>, <a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a> <font color='red'>-4.5%</font>, <a href='https://seekingalpha.com/symbol/BZH' title='Beazer Homes USA, Inc.'>BZH</a> <font color='red'>-1%</font>, <a href='https://seekingalpha.com/symbol/LGIH' title='LGI Homes, Inc.'>LGIH</a> <font color='red'>-1.2%</font>.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a> <font color='red'>-0.8%</font>, <a href='https://seekingalpha.com/symbol/XHB' title='SPDR Homebuilders ETF'>XHB</a> <font color='red'>-0.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277945\" data-linked=\"Homebuilders slide as Barclays downgrades several names\" data-tweet=\"$TOL $TOL $LEN - Homebuilders slide as Barclays downgrades several names https://seekingalpha.com/news/3277945-homebuilders-slide-barclays-downgrades-several-names?source=tweet\" data-url=\"https://seekingalpha.com/news/3277945-homebuilders-slide-barclays-downgrades-several-names\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277943\" data-ts=\"1499785275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277943-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='green'>+51%</font>. <a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/EVGN' title='Evogene Ltd.'>EVGN</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='red'>-34%</font>. PSDV <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277943\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$ARNA $FOLD $OCUL - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3277943-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3277943-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277941\" data-ts=\"1499785085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277941-jefferies-bullish-on-biotechs-sees-127-upside-in-intercept-pharma-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies bullish on biotechs, sees 127% upside in Intercept Pharma; shares ahead 5%</a></h4><ul><li>Thinly traded Intercept Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='green'>+4.5%</font>) is up on light volume after Jefferies initiated coverage with a Buy rating and $275 (127% upside) price target. The company's top product is Ocaliva (obeticholic acid), approved in Canada and the EU for the treatment of a chronic liver disease called primary biliary cholangitis. The big opportunity is NASH, for which Ocaliva is in Phase 3 development.</li><li>Jefferies also likes Celgene (<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='green'>+0.7%</font>) (BUY/$160) and Vertex Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+2.3%</font>) (BUY/$155).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3242518-shortened-timeline-intercepts-late-stage-study-oba-nash-stokes-investors-shares-11-percent\" target=\"_blank\">Shortened timeline for Intercept's late-stage study of OBA in NASH stokes investors, shares up 11% premarket</a> (Feb. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277941\" data-linked=\"Jefferies bullish on biotechs, sees 127% upside in Intercept Pharma; shares ahead 5%\" data-tweet=\"$ICPT $ICPT $CELG - Jefferies bullish on biotechs, sees 127% upside in Intercept Pharma; shares ahead 5% https://seekingalpha.com/news/3277941-jefferies-bullish-on-biotechs-sees-127-upside-in-intercept-pharma-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3277941-jefferies-bullish-on-biotechs-sees-127-upside-in-intercept-pharma-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277934\" data-ts=\"1499783671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277934-best-buy-introduces-new-smart-home-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy introduces new smart home service</a></h4><ul> <li>Best Buy (<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a> <font color='red'>-0.5%</font>) is <a href=\"http://www.startribune.com/best-buy-introduces-service-aimed-at-caretakers-needs/433697203/\" target=\"_blank\">introducing</a> a smart home products designed to help with caregiving duties for adult children monitoring their aging parents. The service will be introduced in the Minneapolis-St. Paul region initially.</li> <li>The personalized caretaking concept allows users to automate many household functions and set up alerts based on motion sensors and cameras.</li> <li>The development is another example of Best Buy's advantage in the connected home space through its Geek Squad and other services. It arrives after news yesterday of Amazon offering in-home repair sent shares of Best Buy into a tailspin.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277616-amazon-mobilizes-geek-squad\" target=\"_blank\">Amazon mobilizes its own 'Geek Squad'</a> (July 10)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277756-sharp-drop-best-buy-seen-overdone\" target=\"_blank\">Sharp drop in Best Buy seen as overdone</a> (July 10)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277934\" data-linked=\"Best Buy introduces new smart home service\" data-tweet=\"$BBY - Best Buy introduces new smart home service https://seekingalpha.com/news/3277934-best-buy-introduces-new-smart-home-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3277934-best-buy-introduces-new-smart-home-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277933\" data-ts=\"1499783382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVRA\" target=\"_blank\">SVRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277933-savaras-aironite-shows-treatment-effect-in-mid-stage-pulmonary-hypertension-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Savara&#39;s Aironite shows treatment effect in mid-stage pulmonary hypertension study; shares ahead 4%</a></h4><ul><li>Thinly traded micro cap Savara (<a href='https://seekingalpha.com/symbol/SVRA' title='Savara Inc.'>SVRA</a> <font color='green'>+4.4%</font>) perks up on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16882745-positive-interim-results-aironite-phase-2-study-presented-4th-annual-drug-discovery\" target=\"_blank\">announcement </a>of positive interim results from a 50-subject, open-label Phase 2 clinical trial assessing Aironite in patients with pulmonary hypertension &#40;PH&#41;. The data were presented at the 4th Annual Drug Discovery and Development Symposium for Pulmonary Hypertension in Berlin.</li><li>In the 41 subjects enrolled to date, Aironite produced the most significant improvements in multiple hemodynamic measures in PH patients due to heart failure with preserved ejection fraction (n=10).</li><li><a href=\"http://savarapharma.com/development/products/\" target=\"_blank\">Aironite</a>, a sodium nitrite solution for inhalation, was generally well-tolerated with no significant safety signals observed. The company intends to advance the product into Phase 3 development.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277933\" data-linked=\"Savara&#39;s Aironite shows treatment effect in mid-stage pulmonary hypertension study; shares ahead 4%\" data-tweet=\"$SVRA - Savara&#39;s Aironite shows treatment effect in mid-stage pulmonary hypertension study; shares ahead 4% https://seekingalpha.com/news/3277933-savaras-aironite-shows-treatment-effect-in-mid-stage-pulmonary-hypertension-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3277933-savaras-aironite-shows-treatment-effect-in-mid-stage-pulmonary-hypertension-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277926\" data-ts=\"1499782204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLS\" target=\"_blank\">SLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277926-galena-amends-again-terms-of-debt-service-lowers-average-price-of-shares-for-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galena amends (again) terms of debt service, lowers average price of shares for interest payments; shares slip 1%</a></h4><ul><li>Galena Biopharma (GALE <font color='red'>-0.8%</font>), the holder of its 6.375% Senior Secured Debenture, JGB Newton Ltd., and the guarantors of the company's obligations under the debt have <a href=\"https://seekingalpha.com/filing/3622836\" target=\"_blank\">agreed to amend</a> the terms for calculating the number of shares used to pay interest. Henceforward, the average price per share issued to pay interest on the debt will be 80% of the volume-weighted average price &#40;VWAP&#41; for the trading day immediately prior to the interest payment date.Previously, the figure was 92.5%. In other words, the discount is now 20% instead of 7.5%.</li><li>The company says that the more generous discount does not change the maximum number of shares issuable related to the debenture.</li><li>The debt agreement was signed in May 2017, following amendments in August 2016 and December 2016.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277926\" data-linked=\"Galena amends (again) terms of debt service, lowers average price of shares for interest payments; shares slip 1%\" data-tweet=\"$SLS - Galena amends (again) terms of debt service, lowers average price of shares for interest payments; shares slip 1% https://seekingalpha.com/news/3277926-galena-amends-again-terms-of-debt-service-lowers-average-price-of-shares-for-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3277926-galena-amends-again-terms-of-debt-service-lowers-average-price-of-shares-for-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277927\" data-ts=\"1499782024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277927-blue-apron-peels-off-7-in-early-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron peels off 7% in early trading</a></h4><ul>     <li>Blue Apron (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>) breaks <font color='red'>7.19% lower</font> as it threatens to hit last week's post-IPO low of $7.36.</li><li>Northcoast Research issues a Sell rating on the stock and lowly $2 price target.</li>     <li>On Seeking Alpha, Galileo Russell <a href=\"https://seekingalpha.com/article/4086724-blue-apron-future-bleak-best\" target=\"_blank\">warns</a> that the company may be forced to raise capital again if operating losses continue.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277927\" data-linked=\"Blue Apron peels off 7% in early trading\" data-tweet=\"$APRN - Blue Apron peels off 7% in early trading https://seekingalpha.com/news/3277927-blue-apron-peels-off-7-in-early-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3277927-blue-apron-peels-off-7-in-early-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277916\" data-ts=\"1499780820\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSTM\" target=\"_blank\">HSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277916-healthstream-shakes-up-management-shares-ahead-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HealthStream shakes up management; shares ahead 1%</a></h4><ul><li>With the aim of supporting growth, HealthStream (<a href='https://seekingalpha.com/symbol/HSTM' title='HealthStream, Inc.'>HSTM</a> <font color='green'>+0.9%</font>) <a href=\"https://seekingalpha.com/pr/16883249-healthstream-announces-management-team-changes\" target=\"_blank\">announces</a> the following management changes:</li><li>Jeff Cunningham appointed SVP and Chief Technology Officer &#40;CTO&#41; effective July 17. He joins the firm from Informatics Corporation of America where he was a founder and served as CTO and Chief Strategy Officer.</li><li>Jeff Doster, SVP and CTO, will transition to role of SVP and Chief Information Officer.</li><li>Tom Schultz, SVP of Sales has resigned to pursue other opportunities.</li><li>Scott Fenstermacher, VP, Solution Sales, promoted to VP &amp; Head of Sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277916\" data-linked=\"HealthStream shakes up management; shares ahead 1%\" data-tweet=\"$HSTM - HealthStream shakes up management; shares ahead 1% https://seekingalpha.com/news/3277916-healthstream-shakes-up-management-shares-ahead-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3277916-healthstream-shakes-up-management-shares-ahead-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277914\" data-ts=\"1499780035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOV\" target=\"_blank\">KTOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277914-kitov-prices-direct-equity-offering-shares-down-34\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kitov prices direct equity offering; shares down 34%</a></h4><ul><li>Thinly traded nano cap Kitov Pharmaceuticals (<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='red'>-33.8%</font>) slumps out the gate this morning in response to its <a href=\"https://seekingalpha.com/pr/16883254-kitov-pharmaceuticals-announces-pricing-3_5-million-registered-direct-offering\" target=\"_blank\">direct offering</a> of 2,431,746 American Depositary Shares (ADSs) at $1.45 per ADS. The company will also issue unregistered warrants to purchase up to 1,215,873 ADSs at $1.50 per ADS.</li><li>Gross proceeds should be ~$3.5M. Closing date is July 14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277914\" data-linked=\"Kitov prices direct equity offering; shares down 34%\" data-tweet=\"$KTOV - Kitov prices direct equity offering; shares down 34% https://seekingalpha.com/news/3277914-kitov-prices-direct-equity-offering-shares-down-34?source=tweet\" data-url=\"https://seekingalpha.com/news/3277914-kitov-prices-direct-equity-offering-shares-down-34\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277909\" data-ts=\"1499779394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277909-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='red'>-29%</font>.</li><li><a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-19%</font>.</li><li><a href='https://seekingalpha.com/symbol/GTY' title='Getty Realty Corp.'>GTY</a> <font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3277866-getty-realty-announces-acquisition-lease-back-deal\" target=\"_blank\">announcing</a> acquisition lease-back deal.</li><li><a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a> <font color='red'>-5%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3277781-barracuda-networks-eps-line-beats-revenue\" target=\"_blank\">earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277909\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$KTOV $YUMA $GTY - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3277909-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3277909-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277906\" data-ts=\"1499779043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277906-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a> <font color='green'>+43%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3277870-halcon-resources-sell-williston-basin-assets-1_4b\" target=\"_blank\">selling</a> Williston Basin assets for $1.4B.</li>     <li><a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='green'>+40%</font><a href=\"https://seekingalpha.com/news/3277784-arena-pharmas-ralinepag-successful-mid-stage-pah-study-shares-27-percent-hours\" target=\"_blank\">&nbsp;announcement&nbsp;</a>of positive results from a Phase 2 clinical trial assessing ralinepag for the treatment of pulmonary arterial hypertension.</li>     <li><a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a> <font color='green'>+33%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3277848-fda-confirms-amicus-therapeutics-may-submit-nda-migalastat-fabry-disease-shares-ahead-28\" target=\"_blank\">probability</a> of submitting NDA for Migalastat for Fabry disease.</li>     <li><a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='green'>+16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3277795-ocular-submits-amendment-dextenza-nda-equipment-change-closes-form-483-issues-fda-action-date\" target=\"_blank\">amendment</a> to Dextenza NDA for equipment change.</li>     <li><a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a> <font color='green'>+16%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3277877-rent-center-rejects-vintage-bid-offer\" target=\"_blank\">rejecting</a> Vintage Bid offer.</li>     <li><a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3277862\" target=\"_blank\">establishing</a> exoskeleton distribution in France.</li>     <li><a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='green'>+7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277906\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$HKRS $ARNA $FOLD - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3277906-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3277906-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277904\" data-ts=\"1499778658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETS\" target=\"_blank\">PETS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277904-craig-hallum-softens-view-on-petmed-express-shares-down-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Craig-Hallum softens view on PetMed Express, shares down 6% premarket</a></h4><ul><li>PetMed Express (NASDAQ:<a href='https://seekingalpha.com/symbol/PETS' title='PetMed Express, Inc.'>PETS</a>) eases&nbsp;<font color='red'>6%</font>&nbsp;premarket on light volume on the heels of a downgrade to Neutral by Craig-Hallum. Analyst Kevin Ellich cites a full valuation, raising his price target to $40 from $31.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3277904\" data-linked=\"Craig-Hallum softens view on PetMed Express, shares down 6% premarket\" data-tweet=\"$PETS - Craig-Hallum softens view on PetMed Express, shares down 6% premarket https://seekingalpha.com/news/3277904-craig-hallum-softens-view-on-petmed-express-shares-down-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3277904-craig-hallum-softens-view-on-petmed-express-shares-down-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277898\" data-ts=\"1499778017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NURO\" target=\"_blank\">NURO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277898-neurometrix-announces-private-placement-of-convertible-preferred-stock-shares-down-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeuroMetrix announces private placement of convertible preferred stock; shares down 19% premarket</a></h4><ul><li>Thinly traded nano cap NeuroMetrix (NASDAQ:<a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a>) slumps&nbsp;<font color='red'>19%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/filing/3622821\" target=\"_blank\">announcement </a>of a direct placement of 7,000 shares of Series F convertible preferred stock at $1,000 per share to an institutional investor. The company expects to receive $7M from the transaction, half initially and half subject to shareholder approval and an effective resale registration statement. Proceeds will fund the commercialization of Quell and working capital.</li><li>Series F shares will be convertible any time into ~2,661,597 common shares at $2.63.</li><li>At the shareholders meeting, the company will also seek approval to reset the conversion price to $2.63 for Series D and Series E convertible preferred shares held by the same investor. It has also agreed to issue 3,621 Series F shares to the investor in exchange for warrants to purchase 4,184,483 common shares.</li><li>The first tranche of the offering should close by July 13.</li><li>Yesterday's close was $2.64.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277898\" data-linked=\"NeuroMetrix announces private placement of convertible preferred stock; shares down 19% premarket\" data-tweet=\"$NURO - NeuroMetrix announces private placement of convertible preferred stock; shares down 19% premarket https://seekingalpha.com/news/3277898-neurometrix-announces-private-placement-of-convertible-preferred-stock-shares-down-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3277898-neurometrix-announces-private-placement-of-convertible-preferred-stock-shares-down-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277892\" data-ts=\"1499777024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APDN\" target=\"_blank\">APDN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277892-applied-dna-inks-multiyear-deal-textile-outfit-ghcl-limited-shares-ahead-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied DNA inks multiyear deal with textile outfit GHCL Limited; shares ahead 9% premarket</a></h4><ul><li>Thinly traded nano cap Applied DNA Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket, albeit on only 350 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16882496-applied-dna-signs-ghcl-certaint-licensee-using-recycled-pet-pet-bedding\" target=\"_blank\">announcement </a>that it signed a multiyear license agreement with home textile maker GHCL Limited to provide CertainT platform services in selected products.</li><li>GHCL will use CertainT in source-verified polyethylene terephthalate &#40;PET&#41; and recycled PET in blended bed sheets, pillowcases and shams sold in-store or online in the U.S. It has also licensed the CertainT trademark to be used on products and in promotional materials.</li><li>The deal specifies minimum annual revenues and trademark licensing royalties to APDN. Specific financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277892\" data-linked=\"Applied DNA inks multiyear deal with textile outfit GHCL Limited; shares ahead 9% premarket\" data-tweet=\"$APDN - Applied DNA inks multiyear deal with textile outfit GHCL Limited; shares ahead 9% premarket https://seekingalpha.com/news/3277892-applied-dna-inks-multiyear-deal-textile-outfit-ghcl-limited-shares-ahead-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3277892-applied-dna-inks-multiyear-deal-textile-outfit-ghcl-limited-shares-ahead-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277891\" data-ts=\"1499776717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGHEF\" target=\"_blank\">PGHEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277891-pengrowth-energy-to-sell-olds-garrington-assets-for-300m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pengrowth Energy to sell Olds/Garrington assets for $300M</a></h4><ul>     <li>Pengrowth Energy (PGH) <a href=\"https://seekingalpha.com/pr/16882748-pengrowth-enters-agreement-sale-olds-garrington-area-assets-300-million\" target=\"_blank\">agrees to sell</a> its Olds/Garrington area assets in central Alberta to a private company for $300M.</li><li>PGH says YTD it has now closed or expects to close $827M of asset sales, which when combined with the $287M of  cash on hand at year-end 2016, represents more than $1.1B in net debt reduction, or 66% of debt held at year-end; the company's year-end 2P reserves have been reduced by only 16%.</li>     <li>PGH also says the buyer of the second Swan Hills sales package is unable to complete its  financing for the deal, forcing the company to terminate the sale agreement.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277891\" data-linked=\"Pengrowth Energy to sell Olds/Garrington assets for $300M\" data-tweet=\"$PGHEF - Pengrowth Energy to sell Olds/Garrington assets for $300M https://seekingalpha.com/news/3277891-pengrowth-energy-to-sell-olds-garrington-assets-for-300m?source=tweet\" data-url=\"https://seekingalpha.com/news/3277891-pengrowth-energy-to-sell-olds-garrington-assets-for-300m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277885\" data-ts=\"1499775357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277885-shire-under-pressure-from-hemophilia-competitors-shares-down-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire under pressure from hemophilia competitors; shares down 4% premarket</a></h4><ul><li>Shire plc (NASDAQ:<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>) is down&nbsp;<font color='red'>4%</font>&nbsp;premarket on increased volume as investors weigh the potential competitive encroachment to its hemophilia franchise. Heading the list is Roche with hemophilia A candidate emicizumab.</li><li>Others recently reporting positive data include BioMarin Pharmaceutical and uniQure.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277717-shire-one-ups-roche-hemophilia-battle-prevails-germany-legal-spat\" target=\"_blank\">Shire one-ups Roche in hemophilia battle, prevails in Germany legal spat</a> (July 10)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277746-uniqures-hemophilia-b-candidate-amtminus-060-shows-long-term-treatment-benefit-mid-stage\" target=\"_blank\">UniQure's hemophilia B candidate AMT-060 shows long-term treatment benefit in mid-stage study; shares up 1%</a> (July 10)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277860-biomarins-gene-therapy-candidate-hemophilia-shows-durable-treatment-effect-mid-stage-study\" target=\"_blank\">BioMarin's gene therapy candidate for hemophilia A shows durable treatment effect in mid-stage study</a> (July 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277885\" data-linked=\"Shire under pressure from hemophilia competitors; shares down 4% premarket\" data-tweet=\"$SHPG - Shire under pressure from hemophilia competitors; shares down 4% premarket https://seekingalpha.com/news/3277885-shire-under-pressure-from-hemophilia-competitors-shares-down-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3277885-shire-under-pressure-from-hemophilia-competitors-shares-down-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277877\" data-ts=\"1499774419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCII\" target=\"_blank\">RCII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277877-rent-center-rejects-vintage-bid-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rent-A-Center rejects Vintage Bid offer</a></h4><ul> <li>Rent-A-Center (NASDAQ:<a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a>) rejects a&nbsp;<a href=\"https://seekingalpha.com/news/3277809-rent-center-plus-26-percent-report-15-share-buyout-bid\" target=\"_blank\">$15</a> per share offer from private equity firm Vintage Bid.</li> <li>The company calls the offer \"inadequate\" and \"opportunistic\" in a SEC fiiing.</li> <li><a href=\"https://seekingalpha.com/filing/3622793\" target=\"_blank\">SEC Form 8-K</a></li> <li>Shares of Rent-A-Center are <font color='green'>up 17.12%</font> premarket to $13.00.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277877\" data-linked=\"Rent-A-Center rejects Vintage Bid offer\" data-tweet=\"$RCII - Rent-A-Center rejects Vintage Bid offer https://seekingalpha.com/news/3277877-rent-center-rejects-vintage-bid-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3277877-rent-center-rejects-vintage-bid-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277870\" data-ts=\"1499773298\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HK\" target=\"_blank\">HK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277870-halcon-resources-to-sell-williston-basin-assets-for-1_4b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halcon Resources to sell Williston Basin assets for $1.4B</a></h4><ul>     <li>Halcon Resources (NYSE:<a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a>) <font color='green'>+12.1%</font> premarket after announcing an <a href=\"https://seekingalpha.com/pr/16882660-halcon-resources-announces-sale-operated-williston-basin-assets-1_4-billion\" target=\"_blank\">agreement to sell</a> its operated assets in the Williston Basin to an  affiliate of Bruin E&amp;P Partners, part of Arclight  Capital Partners, for $1.4B.</li>     <li>HK will retain its non-operated Williston Basin assets, although it may monetize those assets in the future.</li>     <li>HK says the sale transforms it into a single-basin company focused on the Delaware Basin, where it plans to continue to run two rigs for the remainder  of 2017 and currently expects to exit the year with net production of at least 13K boe/day.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277870\" data-linked=\"Halcon Resources to sell Williston Basin assets for $1.4B\" data-tweet=\"$HK $HKRS - Halcon Resources to sell Williston Basin assets for $1.4B https://seekingalpha.com/news/3277870-halcon-resources-to-sell-williston-basin-assets-for-1_4b?source=tweet\" data-url=\"https://seekingalpha.com/news/3277870-halcon-resources-to-sell-williston-basin-assets-for-1_4b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277862\" data-ts=\"1499772410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RWLK\" target=\"_blank\">RWLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277862-rewalk-robotics-establishes-exoskeleton-distribution-in-france-shares-ahead-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ReWalk Robotics establishes exoskeleton distribution in France; shares ahead 14% premarket</a></h4><ul><li>Thinly traded nano cap ReWalk Robotics (NASDAQ:<a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a>) is up&nbsp;<font color='green'>14%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16882488-rewalk-robotics-announces-french-distribution-agreement-harmonie-medical-service\" target=\"_blank\">announcement </a>that it has inked an agreement with Harmonie M&eacute;dical Service &#40;HMS&#41;&nbsp;for the exclusive distribution of the ReWalk exoskeleton in France.</li><li>HMS, established in 1789, will promote the ReWalk Personal systems in home and community environments and the ReWalk Rehabilitation systems in clinical rehab settings with spinal cord injury patients.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277862\" data-linked=\"ReWalk Robotics establishes exoskeleton distribution in France; shares ahead 14% premarket\" data-tweet=\"$RWLK - ReWalk Robotics establishes exoskeleton distribution in France; shares ahead 14% premarket https://seekingalpha.com/news/3277862-rewalk-robotics-establishes-exoskeleton-distribution-in-france-shares-ahead-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3277862-rewalk-robotics-establishes-exoskeleton-distribution-in-france-shares-ahead-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277848\" data-ts=\"1499770394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277848-fda-confirms-amicus-therapeutics-may-submit-nda-for-migalastat-for-fabry-disease-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA confirms Amicus Therapeutics may submit NDA for Migalastat for Fabry disease; shares ahead 28% premarket</a></h4><ul> <li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) <a href=\"https://seekingalpha.com/pr/16882521-u-s-fda-confirms-amicus-therapeutics-may-submit-new-drug-application-migalastat-fabry-disease\" target=\"_blank\">plans</a> to submit a new drug application &#40;NDA&#41; to the&nbsp;FDA for the oral precision medicine <a href=\"https://www.globenewswire.com/Tracker?data=OsDmX6vSDS0MXA_Yd8oyM7jyR58snQv9y_LSD3d5BrEcAMgQBBo1ds1bfSiCsKkvqhKEEaNqqqFhwogv6627AydTaza0cnMKPjSwe3yQDSs=\" target=\"_blank\">migalastat</a> for Fabry disease in&nbsp;Q4.</li>        <li>Amicus is preparing the NDA submission under Subpart H, which provides for accelerated approval. Amicus intends to base its NDA on existing data.</li>    <li>The European Commission has granted full approval for migalastat under the name Galafold,&nbsp;a chaperone therapy that&nbsp;works by stabilizing the body&rsquo;s own dysfunctional enzyme, so it can clear the accumulation of disease substrate in patients who have amenable mutations.</li><li>Marketing applications have also been approved in&nbsp;Switzerland and Israel and&nbsp;regulatory submissions are under review in Japan, Canada and Australia.</li><li>Fabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A, which is the result of mutations in the GLA gene.</li><li>Shares are up&nbsp;<font color='green'>28%</font>&nbsp;premarket on modest volume.</li>                    </ul><div class=\"tiny-share-widget\" data-id=\"3277848\" data-linked=\"FDA confirms Amicus Therapeutics may submit NDA for Migalastat for Fabry disease; shares ahead 28% premarket\" data-tweet=\"$FOLD - FDA confirms Amicus Therapeutics may submit NDA for Migalastat for Fabry disease; shares ahead 28% premarket https://seekingalpha.com/news/3277848-fda-confirms-amicus-therapeutics-may-submit-nda-for-migalastat-for-fabry-disease-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3277848-fda-confirms-amicus-therapeutics-may-submit-nda-for-migalastat-for-fabry-disease-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277843\" data-ts=\"1499769211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEP\" target=\"_blank\">PEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277843-pepsico-beats-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PepsiCo beats estimates</a></h4><ul><li>PepsiCo (NYSE:<a href='https://seekingalpha.com/symbol/PEP' title='PepsiCo Inc.'>PEP</a>) reports organic revenue growth of 3.1% in <a href=\"http://www.pepsico.com/docs/album/q2-2017/q2_2017_fullrelease_5jjnnrhw7rspedgu.pdf\" target=\"_blank\">Q2</a>.</li><li>Foreign exchange translation negatively impacted revenue by 1.5%.</li><li>Revenue by segment: Frito-Lay North America: $3.68B (+3%); Quaker Foods North America: $553M (-1%); Latin America: $1.82B (+6%);&nbsp;North America Beverages: $5.24B (+2%);&nbsp;Europe Sub-Saharan Africa: $2.81B (+6%); AMEA: $1.6B (-8%).</li><li>Frito-Lay North America operating profit expanded 6.4% to $1.16B.</li><li>Europe Sub-Saharan Africa operating profit&nbsp;rose 46.1% to $504M.</li><li>Total core gross margin slipped 5 bps to 55.17%.</li><li>Total core operating margin grew 49 bps to 19.41%.</li><li><b>FY2017 Guidance</b>: Organic revenue growth: ~3%; Core EPS: $5.13; Net capital expenditure: ~$3B; Cash flow from operating activities: ~$10B; Free cash flow: ~$7B; Share repurchases: ~$2B; Dividend payments: ~$4.5B.</li><li>PEP&nbsp;<font color='green'>+0.46%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277843\" data-linked=\"PepsiCo beats estimates\" data-tweet=\"$PEP - PepsiCo beats estimates https://seekingalpha.com/news/3277843-pepsico-beats-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3277843-pepsico-beats-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":49,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}